상품DB/인도 혈액수집튜브 시장동향(2013.10)/관 모양의 금속으로 만든 바늘과 봉합용 바늘

[일출산]

제목

인도 혈액수집튜브 시장동향(2013.10)

게시일

2015-12-04

국가

인도

작성자

문정화(뉴델리무역관)

품목

관 모양의 금속으로 만든 바늘과 봉합용 바늘

품목코드

901832

작성일자: 2013.10.31

작성자: 뉴델리 무역관 Ms. Jaya Nayar (jaya@ktcdelhi.net)

1. Demand Trend

□ Market Trend

 ○ Blood collection equipment and devices

  - Blood and blood components are precious commodities and crucial to survival. Patients who receive blood transfusions or who rely on plasma-derived pharmaceuticals depend on a variety of complex factors all working in concert - availability of blood donors, effective and efficient collection processes at mobile blood drives, and collection centers, and skill in matching the correct blood-type and having the right kind and the right amount of blood available in the hospital when needed. Errors or missteps at any juncture in this process can lead to injury and infection or worse, as well as unnecessary costs. The need for expert blood management along the entire blood supply chain is critical to the healthcare delivery system.

  - Every year millions of blood donations throughout the world produce blood products for transfusion to surgical, trauma, or chronically ill patients. Patients typically receive blood components necessary to treat a particular clinical condition - red cells to surgical patients, platelets to cancer patients, and plasma to trauma victims. Worldwide demand for blood is expected to rise modestly as the population ages and more patients have need for and access to medical therapies that require blood transfusions. Furthermore, highly populated emerging markets are advancing their healthcare coverage and as greater numbers of people gain access to more advanced medical treatment, additional demand for blood components, plasma-derived drugs, and surgical procedures increases directly. This increasing demand for blood is partially offset by the development of less-invasive, lower blood loss procedures. Recently, the economy has also had an effect on demand for blood, as fewer surgeries are performed. The worldwide market for blood components is expected to grow modestly in low single digits.

  - In 2012, Indian blood collection equipment and devices market is estimated at Rs. 102 crore(US$ 18.5 Million).

  - The market for blood collection monitors in 2012 was 517 systems, valued at Rs. 5 crore(US$ 0.9 Million). This compact instrument provides smooth and gentle rocking for homogeneous mixing with anticoagulants without clot formation during blood collection from a donor. Aggressive players in the blood collection monitors segment include Terumo Penpol, REMI, Fenwal, Fresenius, and Skylab Instruments.

  - Blood donor couches had sales of 460 units at Rs. 5 crore(US$ 0.9 Million) in 2012. Couches are available with single, dual, and triple motors. The leading players include Terumo Penpol, Fenwal, Polymed, HLL Lifecare, Skylab Instruments, Fresenius, Insignia, Ultimate Hospicare, Grabner, and Authentic Instruments.

  - A similar sales figure of 460 units was seen for tube sealers, estimated at Rs. 4 crore(US$ 0.72 Million). Also available as dual net tube sealers, they seal the tube of blood bags without causing hemolysis, leakage of blood, and separate the blood through ratio frequency sealing system. Major players in the tube sealer segment include J Mitra, Terumo Penpol, and Fenwal. Regional players such as Bioline and Labtop Instruments have loyal clientele.

  - Blood bags had estimated sales of Rs. 88 crore(US$ 16 Million), with 10.4 million bags sold in 2012. Blood bags and their integrated accessories are high-volume, low-profit products and companies compete on price points. The major players in the blood bags segment include Eastern Medikit, J Mitra, Terumo Penpol, HLL Lifecare, Fenwal, Maco Pharma, Span Healthcare, and Fresenius.

  - The latest penta blood bags prevent wastage as one unit of blood is given to five different recipients. The primary whole blood bags containing anticoagulant solution followed by four small satellite bags make the penta system.

  - There are definite signs that the blood banking and plasma product markets in India are on the upswing. The need for effective usage of donated blood is likely to be one of the key market drivers. Moreover, the government has been making sustained efforts to reinstate donor's and patient's confidence in blood transfusion services. Suppliers to the blood banking and plasma products markets can, therefore, look forward to increased opportunities in this emerging sector within the Indian healthcare industry.

  - India's large and expanding population, as well as the growing demand for blood and blood components are expected to contribute to a greater demand in the blood banking and plasma products market. In addition, rising public demand for safer blood donation and transfusion services is likely to create a strong case for more automated blood collection devices, as well as leading to the increased use of leukocyte reduction filters.

 

Source: Medical Buyer Magazine (March 2013)

Source: Medical Buyer Magazine (March 2013)

Source: Medical Buyer Magazine (March 2013)

 ○ Technological Advancements

  - Though blood and blood components provided by blood banks are free from viruses, bacteria, and other disease causing microorganisms, safety has become the main issue the world over. Risks involved in blood transfusion have also become a major issue in the blood banks industry. Many companies are now visualizing blood decontamination as a step toward blood safety and availability. Though the process does not do away with the traditional blood screening, and donor exclusion programs, it is expected to prevent infected transmission. New processes are being developed to make blood supply safer. Areas such as blood filtration and pathogen passivation methods are witnessing development.

  - Advancements in blood safety have resulted in a greater need for pathogens detection, their removal, and inactivation. Modern tests based on detecting nucleic acids instead of conventional antibody proteins have been developed to recognize viruses. Leukocyte removal, in the form of separate and in-built filters, is a significant driver for the Indian blood banking devices market. Since leukocytes are one of the main vectors for transmission of bacteria and viruses to the recipient, removing them from donor's blood increases safety for the recipients.

  - The traditional way of collecting blood is through blood bags and their integrated accessories. However, automated alternatives such as apheresis and autologous devices and disposables are steadily gaining momentum. Plasmapheresis has become a routine form of blood donation, and is now an important source of plasma procurement. Procedures and equipment for plasmapheresis may differ, but the basic act of bleeding the donor and safely returning the packed red cells remains the same.

  - Blood bags and their integrated accessories belong to high-volume low-profit products, and companies mainly compete through price. Over the past 10 years, price erosion has dominated, causing low profit margins. This trend is likely to accelerate within the next three years, and may only stabilize in the long term if new features are launched.

  - Blood collection monitors are being introduced with advanced features like multiple donor management, fully automated software systems pre-installed for having more control on the quality of blood collections, and health of the donor while donating. Blood collection monitors with high-precision programmed blood volume collection and continuous agitation for avoiding clot formation are also remarkable advancements. Online blood collection monitoring helps in effective data management systems and enables healthcare providers to have better way to trace the quality of blood collections.

  - Rapid-charging facilities of tube sealers for ensuring continuous high quality sealing with comparatively less times of charging are a new technology in this segment. Blood donor couches are now changed into blood donor stations, with full facilities for complete donor care. The designs of donor stations are now without full body movement during vasovagal attacks, to give critical care to the donor.

  - Automated devices such as apheresis and whole blood collection and processing devices gain market share at the expense of the manual blood collection segment. Pro-automation arguments are mainly overcoming the obstacles of cost pressures and increased regulatory strictness about blood safety. Collecting and processing blood through automated devices saves time, increases efficiency, and therefore, lessens the overall operational cost from the end-users side. Quality management according to regulatory demand can also be better ensured. Another important aspect of automation is the decreased amount of donors needed, thus, less exposure to pathogen and bacterial infection throughout the entire process.

  - In India, despite all technological advancements available for usage, blood transfusion services are plagued by fragmented management, a non-conducive environment for blood safety. In the country, blood collection, storage, and delivery occur mainly in blood banks attached to hospitals most of which are under central and state government control. A significant portion of blood banking activity is also done by voluntary agencies and private sector blood banks. While the collection of blood demonstrates no absolute shortages, there are occasional and seasonal shortages.

 ○ Challenges and Opportunities

  - Large players primarily compete on safety, technological advancement, performance, and pricing grounds. Obtaining on-time regulatory clearances is also crucial for the success of products. Medical devices companies across the world are facing increasing pricing pressure owing to government mechanisms to restrain healthcare expenditure and provide cost relief to the consumer. Escalating raw material and shipping costs, leading to erosion in profit margins, also pose a major challenge for manufacturers.

  - While price competition is globally seen as an obstacle for all suppliers within the manual blood banking devices segment, European manufacturers and distributors suffer further from the high end-user purchasing power. Over 95% of blood bags are sold to national blood banks, with less than 5% going to hospitals for use in the transfusion process. Both end-users buy in bulk, mostly through annual or biannual tenders. Purchasing in vast volume restricts the flexibility in price negotiation. Furthermore, national blood banks are publicly funded organizations and as such strongly subjected to cost containment. Consolidation of end-users is another trend, which further increases their existing high purchasing power. National blood banks as well as hospitals are merging and forming groups together in order to increase their operational efficiency.

  - The main challenge for all affected companies in this market is not only to maintain their competitiveness within the manual blood banking devices market but also to secure and expand their position within one or several automated segments.

 ○ Blood Collection Tubes

  - There is no specific market information about blood collection tubes, this being a very specific and highly fragmented market.

  - The market for tubes(blood collection tube) in India in 2010 was 9 Million tubes which are expected to double i.e. 18 Million tubes in next three years.

  - Various factors such as rising preval‎ence of diseases, improving affordability of patients and increasing penetration of health insurance have contributed substantially to spur demand for diagnostic services in the country. Another important factor is the emergence of India as an outsourcing hub for clinical trials and research and development activities of global pharmaceutical companies leading to an increased demand for these services.

  - The blood collection tubes manufactured in India are non-vacuum type. Vacuum blood collection tubes are usually imported from overseas. However a handful of Indian companies have also started the manufacturing of vacuum blood collection tubes.

  - The major players for blood collection tubes in India are BD(Becton Dickinson, India) and Greiner India. According to industry sources, BD now manufacturers blood collection tubes in India. Greiner products are still imported.

  - As per industry sources, prices play an important factor in the blood collection tubes business. Both the major players offer very reasonable and competitive prices for their products, and with good brand names and less price, their products are the most demanded in the vacuum collection tubes market.

  - As there are no specific published details and information on the blood collection tubes, we are giving hereunder brief about Indian diagnostics and pathology testing market for the reference and understating of Korean company.

 ○ Indian diagnostics and pathology testing market

  - The Indian diagnostics market can be broadly divided into equipment and services. The service sector is largely unorganized, with a large presence of players located at the regional or city level.

  - Backed by immense potential characteristics including a large population of qualified clinicians, huge number of patients, cost-efficient treatments, and a well-trained medical community, the lab services market, a leading segment of the Indian diagnostics market, is estimated to grow at a CAGR of around 26% during 2012~2015.

  - India's diagnostics sector is largely fragmented and the organized sector contributes only 10% of the total market. The share of the organized sector in the total market is likely to reach 50% in the coming decade.

  - The Indian diagnostics giants are expanding their presence not only in India, but also in overseas territories like the Middle East and the United States. The spectrum of their test menu is expanding in the areas of genetics, cancer, endocrinology, infectious diseases, and molecular diagnostics. They are coming up with various business models to penetrate not only tier-I, but also tier-II and tier-III cities. The organized segment can explore the opportunities of expanding to semi-urban and rural areas. Mergers and acquisitions would be a likely route for expansion.

  - India is fast becoming the preferred destination for high-end pathology and diagnostic services.

  - Many foreign medical services companies are outsourcing their specialized laboratory tests to India.

  - It is proving to be a very profitable win-win situation, with India reaping the benefits of the new business and the foreign medical companies saving huge sums of money on lab fees.

   · Pathology is becoming the next big outsourcing vehicle in India.

  - An increasing number of hospitals from the UK, US, Middle East and neighboring countries are tying up with Indian diagnostic centers to conduct laboratory tests.

   · For the foreign hospitals and medical companies, it can amount to savings of up to 40%, while for India, it means more revenue.

  - Packaged samples are flown to India for testing and after being analyzed online reports are drawn up and sent back to the client hospital.

  - At the moment, only specialized tests in the areas of genetics, cancer and infectious diseases are being outsourced, but pathologists feel the business is set to grow.

  - In India, the in-vitro segment of the industry accrued revenues of US$ 463.50 million in 2012, which is estimated to touch US$ 1,254 million by 2018. The principal areas of growth include hematology, biochemistry, haematology, molecular diagnostics and specialty diagnostics. The increase in the number of hospitals and healthcare facilities, development of healthcare infrastructure and the advancement of medical equipment propelled the growth of this industry. Further, the increase in the complexity of diseases has prompted the industry to provide better facilities for diagnosis and sample collection.

  - The imaging-diagnosis segment generated revenues of US$ 645.10 million in 2012, projected to reach US$ 1,000 million by 2018. With increased awareness and investments in advanced technology pouring into the segment, the sector has developed considerably over the past five years. One of the prime needs of the imaging diagnosis industry is skilled labor. Currently, many seminars, training programs and workshops are being conducted to educate professionals on the operation and use of advanced radio-imaging techniques.

  - Finally, the Indian diagnostic and pathology services market has seen a boom in the last five years. A strong driver for this segment is an increase in spending power, which has made sophisticated tests more affordable. Diabetes, orthopedic and cardiovascular problems need the services of this segment very often. In 2012, the segment generated revenues of US$ 2.2 billion and is estimated to reach 2.47 billion in 2013. It is expected to grow at a CAGR of 12% to reach US$ 4.37 billion by 2018.

  - Around US$ 220 Million is managed by organized sector comprising handful of top laboratories. The industry is highly competitive and price-driven with kickbacks and business referral payments in the absence of a regulatory body. Around 70% of the treatment decisions in the country are based on lab results.

  - Industry experts cite emergence of the country as a preferred global R &D hub, expansion of the clinical trials market, opening up of the health insurance industry for privatization, consolidation amongst organized players, increased health awareness and quality consciousness in urban India resulting in an increased test prescription rate and Public-Private Partnerships(PPP) as the major reasons for the boom.

  - There are 40,000 independent path labs in the country and the industry is highly competitive and price-driven with kickbacks and business referral payments in the absence of a regulatory body.

  - In India, the diagnostics sector has been witnessing immense progress in innovative competencies and credibility. Technological advancements and higher efficiency systems are taking the market to new heights. The use of advanced and cutting-edge technologies in understanding a disease prognosis has further strengthened the sophistication level of participants in the sector.

  - Rapidly rising automation needs along with the rising incidence of diseases are consistently driving the growth of the Indian diagnostics market. The increasing number and complexity of tests, coupled with a shortage in laboratory staff, is leading to a greater level of automation in laboratories. Labor accounts for around 65% of operating expenses in a typical laboratory, and automating a laboratory can expand its capabilities while achieving significant savings.

  - Emergence of the country as a preferred global R &D hub, expansion of the clinical trials market, opening up of the health insurance industry for privatization, consolidation amongst organized players, rising income of the middle and lower-income class population, increased health awareness and quality consciousness in urban India resulting in an increased test prescription rate, and public-private partnerships(PPP) are driving the market. The government is taking initiatives in boosting up the healthcare sector by entering into PPP and attracting inflows of foreign direct investments in the diagnostics sector. Entering into partnership with the government at various levels can help private diagnostics players to enter the difficult rural market and expand at a larger scale. While certain initiatives have been taken in healthcare services, PPP in diagnostics as an exclusive service are at an embryonic stage.

  - So far dominated by local unorganized players, dynamics for diagnostics sector in India are set for a re-vamp with the entry of foreign players and home-grown players consolidate to take advantage of the increasing demand driven by rising disposable income, increase in lifestyle diseases, consumer awareness, and changing regulatory landscape. Outsourcing by hospitals to external referral laboratories known as hospital laboratory management(HLM) has given diagnostics industry the much-required impetus.

  - The growing interest in personalized medicine is driving the genetic testing market across the world. Various pharmacogenomic tests are used for the prognosis and diagnosis of diseases. The increasing application of genetic testing for the diagnosis of infectious diseases is driving the overall market growth. Most laboratories are now using genetic tests for the diagnosis of infectious diseases, especially for sexually transmitted diseases such as AIDS/HIV. Apart from STDs, companies are now focusing on developing a rapid test for the detection of respiratory diseases.

 ○ Demand for Decentralized Laboratory Testing

  - The healthcare delivery system has undergone a transition from hospital delivery to POC(Point-of-care). Many factors have contributed to this shift from central laboratory testing to POC testing. In POC testing, the TAT(Turn-around-time) is short as results are rapid and treatment starts without any delay as the time of sample transfer to central labs and then report generation and transfer steps are eliminated.

  - Technological advances have also enabled POC testing to be more effective. The integration of IT with POC testing devices has improved data management and connectivity. The connectivity has enabled real-time information exchange between patients and physicians leading to on-time treatment. This subsequently leads to improved patient satisfaction, which drives the demand for POC testing.

  - Accessibility is another major factor that plays a role in patients preferring for POC testing. These tests need minimal infrastructural requirements and can be performed in settings such as physicians' offices, emergency rooms, intensive care units, and patients' homes.

  - The demand for POC testing is growing significantly in emerging countries as there are a limited number of hospitals and central laboratories and the need for healthcare is constantly increasing. These factors are leading to overcrowded hospitals and long waiting times, which cause delays to treatment and patient dissatisfaction. POC testing is the preferred option to meet the growing needs of patients in countries with poor healthcare infrastructure, as POC tests can be conducted in any setting and minimize the need for proper infrastructure.

2. Major players in the market

□ Becton dickinson(BD)

 ○ BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.

 ○ BD operates in India through a wholly-owned subsidiary - BD India Pvt. Ltd. BD has a world-class manufacturing plant at Bawal, Haryana that has a capacity to manufacture over a billion medical devices of Class II and IIa disposable needles and syringes using a highly automated process as per global standards. The plant has also been recognized by the Haryana State Industrial Corporation.

 ○ Products by the company

  - Blood Specimen Collection - Venous Blood (BD Vacutainer? Tubes, Needles and Accessories)

	Chemistry Tubes (BD Vacutainer? SST™ GEL Tubes for Serum Chemistry)
	Chemistry Tubes (Plain BD Vacutainer? Tubes for Serum Chemistry)
	Chemistry Tubes (Heparin BD Vacutainer? Tubes for Plasma Chemistry)
	Chemistry Tubes (BD Vacutainer? Tubes for Glucose Estimation)
	Special Chemistry Tubes
	Haematology Tubes (BD Vacutainer? Tubes with EDTA for Whole Blood)
	Coagulation Tubes (BD Vacutainer? Tubes with Buffered Na. Citrate)
	Immunology/ Molecular Biology Tubes
	Microbiology Tubes
	Blood Banking Tubes
	Needles & Accessories

 ○ India head office

  - 6th Floor Signature Tower – B, South City I, NH 8, Gurgaon, 122001, Haryana, India

  - Tel: 91-124-3949390, 2383566 - 71

  - Fax: 91-124-2383224-25-26

  - E-mail: bd_india@bd.com

  - http://www.bd.com/india/aboutus.asp

□ Greiner India

 ○ Today, the Greiner Group, which is based in Kremsmuenster (Upper Austria), is a Global Player in the plastics sector. With a production and distribution network in more than 100 countries worldwide and approximately 1500 employees, the company has been extremely successful in both product divisions. Greiner Bio-One is a global leader in the HTS product sector for the pharmaceutical screening of active agents. In the area of specimen sampling devices, the Greiner Group has been achieving high market share profits for years and has consequently become market leader in a number of regions already.

 ○ Products by the company

  - The brand name Vacuette? has become synonymous with progress and innovation in specimen collection. Like most other trendsetters, the Vacuette? System has often been copied, but never successfully imitated in terms of quality and safety.

   · All components of the Vacuette? System are available in different versions, in a broadly diversified product line. The Vacuette? Blood Collection Tube range covers all requirements in the modern routine laboratory as well as in the specialized laboratory. The tube holder and venipuncture system can be selected depending on the patient’s individual vein conditions and varying safety requirements.

	Clinical Chemistry
	Coagulation Analysis
	Haematology
	Blood Sedimentation
	Glucose Determination
	Molecular Diagnostics
	Special Diagnostics

 ○ Greiner Bio-One (India) Pvt. Ltd.

  - Phone: (+91) 120 456 8787

  - Fax: (+91) 120 456 8788

  - E-Mail: info@gboindia.com

  - http://www.gbo.com

□ Poly medicure limited

 ○ Polymed was conceived and established by a group of engineers and technocrats dedicated to the idea of providing the benefits of modern healthcare to the mankind at affordable price. This unique philosophy has been the driving force behind the company since its inception in 1995. Today it has grown into one of the most dynamically versatile manufacturers of Medical devices globally with over 75 different products.

 ○ Polymed manufactures its products using state of the art technology in ultra modern facilities covering over 300,000 square feet of manufacturing floor space with about 50,000 square feet of clean rooms of class 100,000 to class 1,000. A tool room with modern facilities & CNC machines supports the manufacturing processes. A high degree of automation and an effective process control helps in delivering consistent product quality.

 ○ Polymed's core strength is its fully committed, well trained and technically competent personnel. A highly qualified, experienced and motivated management provides guidance and support to the team of over 1800 people employed in different activities.

 ○ To keep pace with the ever changing requirements of the market, Polymed has a fully staffed and highly equipped R &D section approved by Ministry of Science & Technology, Government of India, to design and develop new and innovative products.

 ○ Poly Medicure has set up a plant to manufacture 5 Crore blood collection tubes per annum to cater to this growing demand. It has already started a new division with 10 persons in 2009 and will add another 15 persons in sales and marketing within next six months all over India. For export sales, the company is tying up with existing network of dealers and distributors. It expects a revenue of approx. Rs 20 crore from this division in 2012. Poly Medicure Ltd will also be spending Rs 50 crore in next two years to expand manufacturing capacities in existing plants and setup a new plant in Jaipur - SEZ.

 ○ Products by the company

  - Haemochek - Blood Collection Tubes

  - Features of Haemochek Blood Collection Tubes

  - Vacuum blood collection tubes are made of PET or glass having unique biocompatibility.

  - Easy, quick & safe venous blood collection with improved patient comfort.

  - Completely closed circuit system

  - Prevents blood contamination and spill over

  - Minimizes needle stick injuries to phlebotomist & patient

  - Save time and improves efficiency in clinical labs

  - Universal color-coding for easy identification

  - More precise diagnostic & therapeutic decisions by physicians

   · Precise volume of blood collection and further mixing with desired volume of additive in blood collection tubes

Haemochek Serum Tubes
8003, 8004, 8005, 8006, 8007 & 8010
Haemochek Serum Separating Tube with Gel Separator
8403, 8404, 8405, 8406, 8407 & 8410
Haemochek Coagulation (Citrate) Tubes
8102, 8103 & 8104

Source: http://www.polymedicure.com

□ Alchem diagnostics

 ○ Established in the year 1996, Alchem Diagnostics is a renowned manufacturer and supplier of medical products and includes diagnostic and research disposable products. These products find their wide application in medical &health care industry such as hospitals, medical fraternity, laboratories, pharmaceutical industry and microbiological sector.

 ○ Product: Biovac Tubes

  - The company offers clients a variety of blood collection vacuum tubes. As name suggests these tubes are widely used for collecting blood samples in the medical industry. These tubes are manufactured using advanced machines and quality raw material.

  - The range of blood collection vacuum tubes offered by us comprises following:

   · Heparin Tubes

   · EDTA Tubes

   · Plain Clot Tubes

   · Fluoride Tubes

   · Citrate Tubes

 ○ Alchem Diagnostics

  - Mr. Ganesan Marappan (CEO)

  - Address: No. 78, Gokhale Street, Ramnagar, Coimbatore - 641 009, Tamil Nadu, India

  - Mobile: 91-9790499796, 9865455999

  - Telephone: 91-422-2231232, 2235232

  - http://www.bioproindia.com/

□ Scan diagnostics

 ○ Scan Diagnostics a Mumbai, India based company was incorporated in year 2004 with clear vision to provide unmatched services with quality products to the Indian Pharmaceutical & Medical Diagnostic Industry. The company imports products from China.

 ○ Product: Vacuum Blood Collection Tubes:

  - Multiple-sampling blood collection system that utilizes vacuum method of collection. The method of collection virtually eliminates syringe draws & provides a closed connection for line draws. The system includes tubes in a full range of volumes in PET Tubes and additives, multi-sampling needles with pre-assembled holders, needle protection devices, and safety winged blood collection sets.

  - These are Sterile Disposable Square Petri Plates Optically clear, transparent, useful for carrying out bioassay and antibacterial sensitivity test.

 ○ Scan Diagnostics

  - Address: K 129, Sri Raj Laxmi Complex, Kalher, Bhiwandi, Thane, Maharashtra-421320 India

  - Tel: 91-2522-276214

  - E mail: info@scandiagnsoticsindia.com

  - http://www.scandiagnosticsindia.com

□ CPC diagnostics Pvt. Ltd.

 ○ CPC Diagnostics Pvt. Ltd. is a dedicated provider of products and services to the Clinical Laboratory industry in India, Sri Lanka and Bangladesh. The experience and expertise that we have gained since we began in 1987 have made us a respected and trusted organization. CPC has entered into a technical collaboration with AL Systeme, Germany, to manufacture Haematology analyzers in India through its manufacturing arm CPC Medical Systemz.

 ○ They deal with Soyagreentec blood collection tubes importing and distributing in India. However the company said the products of major players in the market(BD and Greiner) are very price competitive and reasonably cheap than other imported products.

 ○ Product: Ampulab

  - CPC has introduced complete range of Vacuum blood collection tubes for pre-analytical requirement of the customers of all the segments. These Products have US FDA registration for sterilization facility, CE Certified, ISO 9011:2000, EN ISO 13485:2003 and EN ISO 11137:1995 certified.

 ○ CPC Diagnostics Pvt. Ltd.

  - Mr. Prasanth T. K. (General Manager)

  - No. 9, 5th Floor, Gokul Tower, No. 9 & 10, C. P. Ramaswamy Road, Alwarpet

  - Chennai - 600018, Tamil Nadu, India

  - Mobile: 91-7303271994

  - Telephone: 91-44-24993989, 23460161

  - Fax: 91-44-24993357

  - http://www.cpcdiagnostics.in/

3. Import Trend

□ Import Tariff

HS Code	901832
Item Description	Tubular metal needles and needles for sutures
Total import Duty (%)	18.943
Duty Structure (%)	Basic Duty(BD): 7.5 Countervailing Duty(CVD): 6 Special CVD(SCVD): 4 Educational Cess(EC): 3

 ○ Indian companies mostly use the following HS Code for import, export of blood collection tubes:

HS Code	90183990
Item Description	Instruments and Appliances used in medical, surgical, dental, or veterinary sciences: Other
Total import Duty (%)	18.943
Duty Structure (%)	Basic Duty(BD): 7.5 Countervailing Duty(CVD): 6 Special CVD(SCVD): 4 Educational Cess(EC): 3

 ○ India-Korea CEPA Tariff:

  - HS Code 901832 and 90183990 products are included in Indo-Korea CEPA regulation and the CEPA type is E-5 therefore the tariff is reduced gradually till 2014.

  - Please find below chart for the calculated tariff.

□ Import Statistics

HS Code 901832

                                                                                                                 (Unit: US$, %)

Rank	Partner Country	Value				Share
		2010	2011	2012	2013.1~6	2010	2011	2012
-	World	23,391,596	35,515,919	36,307,565	18,306,993	100	100	100
1	Singapore	3,343,256	4,743,228	7,852,198	4,558,515	14.29	13.36	21.63
2	United States	4,627,755	6,499,372	5,050,450	2,495,128	19.78	18.3	13.91
3	Japan	4,100,435	5,419,984	4,097,281	1,783,225	17.53	15.26	11.28
4	France	2,309,126	3,740,272	3,612,316	1,990,552	9.87	10.53	9.95
5	China	1,731,626	4,534,005	3,038,232	2,106,247	7.4	12.77	8.37
6	Brazil	1,540,533	1,902,443	1,969,201	727,079	6.59	5.36	5.42
7	Malaysia	969,835	473,860	1,562,539	102,872	4.15	1.33	4.3
8	Korea, South	1,018,041	1,335,979	1,405,784	292,816	4.35	3.76	3.87
9	Vietnam	0	815,246	1,296,139	426,951	0	2.3	3.57
10	Thailand	48,904	144,259	1,080,287	410,548	0.21	0.41	2.98

Source: Global Trade Altas

Source: Global Trade Altas

HS Code 90183990

                   (Unit: US$, %)

Rank	Partner Country	Value				Share
		2010	2011	2012	2013.1~6	2010	2011	2012
-	World	101,864,086	111,463,507	110,772,984	64,621,017	100	100	100
1	United States	39,091,796	31,249,072	21,809,630	15,028,963	38.38	28.04	19.69
2	Ireland	9,645,569	6,214,214	17,264,920	16,349,942	9.47	5.58	15.59
3	Germany	8,886,887	20,875,245	15,913,523	7,943,942	8.72	18.73	14.37
4	Singapore	5,097,417	2,504,459	11,155,900	3,581,669	5	2.25	10.07
5	China	8,042,248	12,619,878	10,299,223	3,104,801	7.9	11.32	9.3
6	Japan	3,921,174	4,694,421	7,540,313	3,528,176	3.85	4.21	6.81
7	Malaysia	7,554,740	6,955,887	5,491,516	4,178,166	7.42	6.24	4.96
8	France	5,738,464	4,935,924	3,892,940	1,844,176	5.63	4.43	3.51
9	Mauritius	364,787	537,572	3,688,317	2,228,232	0.36	0.48	3.33
10	Switzerland	3,416,977	6,046,241	3,615,718	988,257	3.35	5.42	3.26
11	Mexico	404,055	689,957	1,603,079	704,478	0.4	0.62	1.45
12	Thailand	1,627,487	1,005,616	1,327,251	740,067	1.6	0.9	1.2
13	Belgium	768,653	1,057,185	981,985	131,086	0.75	0.95	0.89
14	Italy	506,425	1,248,475	960,319	348,179	0.5	1.12	0.87
15	United Kingdom	796,765	808,303	815,361	447,657	0.78	0.73	0.74
16	Korea, South	467,866	1,604,508	759,400	827,433	0.46	1.44	0.69

Source: Global Trade Altas

Source: Global Trade Altas